B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Clinical trials for B-CELL NON-HODGKIN LYMPHOMA (B-NHL) explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON-HODGKIN LYMPHOMA (B-NHL) trials appear
Sign up with your email to follow new studies for B-CELL NON-HODGKIN LYMPHOMA (B-NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug PIT565 takes on tough blood cancers in early trial
Disease control OngoingThis early-phase study tests a new biologic drug called PIT565 in 61 adults with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see ho…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for tough lymphoma: experimental drug faces standard care in phase 3 showdown
Disease control OngoingThis study tests an experimental drug, odronextamab, in people with aggressive B-cell non-Hodgkin lymphoma that has come back or no longer responds to treatment. About 216 participants will receive either the new drug or standard therapy to compare safety, effectiveness, and qual…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New antibody drug shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis Phase 2 trial tests an investigational drug called odronextamab in 515 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The main goal is to see if it shrinks tumors a…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC